Session Type: Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose: To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis.
Methods: In this longitudinal cohort study, anti-cortactin autoantibody tiers were assessed by ELISA in 670 adults and 343 juvenile myositis patients as well as 202 adult and 90 juvenile healthy controls. The prevalence of anti-cortactin autoantibodies was compared among groups. The clinical features of patients with and without anti-cortactin autoantibodies were also compared.
Results: The prevalence of anti-cortactin autoantibodies was not different between all adult myositis patients compared to adult healthy controls (11% vs. 8%; p=0.2). However, compared to adult healthy controls, anti-cortactin autoantibodies were more common in adult dermatomyositis (DM) patients (15%, p=0.005), particularly those with co-existing anti-Mi2 (24%, p=0.03) or anti-NXP2 (23%, p=0.04) autoantibodies. In adult myositis, anti-cortactin was associated with DM-skin involvement (62% vs. 38%, p=0.03), dysphagia (36% vs. 17%, p=0.02) and co-existing anti-Ro52 (47% vs. 26%, p=0.001) or anti-NT5C1a autoantibodies (59% vs. 33%, p=0.001). Moreover, the titers of anti-cortactin antibodies were higher in patients with interstitial lung disease (0.15 vs. 0.12 arbitrary units, p=0.03). The prevalence of anti-cortactin autoantibodies was no different in juvenile myositis (2%) or any juvenile myositis subgroup compared to juvenile healthy controls (4%). Nonetheless, juvenile myositis patients with these autoantibodies had a higher prevalence of mechanic’s hands (25% vs. 7%; p=0.03), a higher number of hospitalizations (2.9 vs. 1.3, p=0.04) and lower peak CK values (368 vs. 818 IU/L, p=0.02).
Conclusion: The prevalence of anti-cortactin autoantibodies is only increased in adult DM patients with co-existing anti-Mi2 or anti-NXP2 autoantibodies. In adults, anti-cortactin autoantibodies are associated with dysphagia and interstitial lung disease.
To cite this abstract in AMA style:Pinal-Fernandez I, Pak K, Gil-Vila A, Baucells A, Plotz B, Casal-Dominguez M, Derfoul A, Martinez M, Selva-O'Callaghan A, Sabbagh S, Miller F, Rider L, Christopher-Stine L, Mammen A. Anti-cortactin Autoantibodies Are Associated with Key Clinical Features in Adult Myositis but Are Rarely Present in Juvenile Myositis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/anti-cortactin-autoantibodies-are-associated-with-key-clinical-features-in-adult-myositis-but-are-rarely-present-in-juvenile-myositis/. Accessed January 18, 2021.
« Back to ACR Convergence 2020
ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-cortactin-autoantibodies-are-associated-with-key-clinical-features-in-adult-myositis-but-are-rarely-present-in-juvenile-myositis/